• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (132)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Public Health  • Tobacco  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Cheryl Oncken, MD; David Gonzales, PhD; Mitchell Nides, PhD; Stephen Rennard, MD; Eric Watsky, MD; Clare B. Billing, MS; Richard Anziano, MS; Karen Reeves, MD; for the Varenicline Study Group

Arch Intern Med. 2006;166:1571-1577.

Background  The selective nicotinic acetylcholine receptor partial agonist, varenicline tartrate, represents a novel type of therapy for smoking cessation. This study evaluated the efficacy, safety, and tolerability of 4 varenicline dose regimens, 2 with progressive dosing over the first week (eg, titrated) and 2 with a fixed dosing schedule (eg, non-titrated), for promoting smoking cessation.

Methods  This multicenter, double-blind, placebo-controlled study randomized healthy smokers (aged 18-65 years) to varenicline tartrate, 0.5 mg twice daily nontitrated (n = 129), 0.5 mg twice daily titrated (n = 130), 1.0 mg twice daily nontitrated (n = 129), 1.0 mg twice daily titrated (n = 130), or placebo (n = 129) for 12 weeks to aid in smoking cessation. A 40-week follow-up period assessed long-term efficacy. The primary efficacy measures were the carbon monoxide–confirmed 4-week continuous quit rates by pooled dosage group for weeks 4 through 7 and 9 through 12 and the continuous abstinence rates for weeks 9 through 52.

Results  Weeks 9 through 12 continuous quit rates were greater in the 1.0-mg group (49.4%) and the 0.5-mg group (44.0%) vs placebo (11.6%; P<.001 vs both doses). Weeks 9 through 52 abstinence rates were greater in the 1.0-mg group (22.4%; P<.001) and the 0.5-mg group (18.5%; P<.001) vs placebo (3.9%). Varenicline was generally well tolerated, with nausea occurring in 16% to 42% of varenicline-treated subjects. Reports of nausea were lower for the titrated vs nontitrated dosing and infrequently led to medication discontinuation.

Conclusion  Varenicline tartrate, 0.5 mg and 1.0 mg twice daily, is efficacious for smoking cessation.

Author Affiliations: University of Connecticut Health Center, Farmington (Dr Oncken); Oregon Health & Science University, Portland (Dr Gonzales); Los Angeles Clinical Trials, Los Angeles, Calif (Dr Nides); University of Nebraska Medical Center, Omaha (Dr Rennard); and Pfizer Global Research and Development, Groton, Conn (Drs Watsky and Reeves and Ms Billing and Mr Anziano).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

New Weapon to Curb Smoking: No More Excuses to Delay Treatment
Bankole A. Johnson
Arch Intern Med. 2006;166(15):1547-1550.
EXTRACT | FULL TEXT  

Cytisine for Smoking Cessation: A Literature Review and a Meta-analysis
Jean-François Etter
Arch Intern Med. 2006;166(15):1553-1559.
ABSTRACT | FULL TEXT  

Smoking Cessation With Varenicline, a Selective 42 Nicotinic Receptor Partial Agonist: Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up
Mitchell Nides, Cheryl Oncken, David Gonzales, Stephen Rennard, Eric J. Watsky, Rich Anziano, Karen R. Reeves, and for the Varenicline Study Group
Arch Intern Med. 2006;166(15):1561-1568.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of Moderate-Dose Treatment With Varenicline on Neurobiological and Cognitive Biomarkers in Smokers and Nonsmokers With Schizophrenia or Schizoaffective Disorder
Hong et al.
Arch Gen Psychiatry 2011;68:1195-1206.
ABSTRACT | FULL TEXT  

A Randomized Placebo-Controlled Trial of Varenicline for Smoking Cessation Allowing Flexible Quit Dates
Rennard et al.
Nicotine Tob Res 2011;0:ntr220v1-ntr220.
ABSTRACT | FULL TEXT  

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis
Singh et al.
CMAJ 2011;183:1359-1366.
ABSTRACT | FULL TEXT  

How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey
Le Strat et al.
Tobacco Control 2011;20:338-343.
ABSTRACT | FULL TEXT  

Pharmacotherapy for smoking
Allan et al.
cfp 2011;57:47-47.
FULL TEXT  

Mental health stability in veterans with posttraumatic stress disorder receiving varenicline
Campbell and Anderson
Am J Health Syst Pharm 2010;67:1832-1837.
ABSTRACT | FULL TEXT  

Do point prevalence and prolonged abstinence measures produce similar results in smoking cessation studies? A systematic review
Hughes et al.
Nicotine Tob Res 2010;12:756-762.
ABSTRACT | FULL TEXT  

Pharmacological treatment for smoking cessation
Jimenez-Ruiz
Smoking Cessation 2010;1:74-97.
ABSTRACT  

Mouse model predicts effects of smoking and varenicline on event-related potentials in humans
Rudnick et al.
Nicotine Tob Res 2010;12:589-597.
ABSTRACT | FULL TEXT  

Gabapentin for smoking cessation
Sood et al.
Nicotine Tob Res 2010;12:300-304.
ABSTRACT | FULL TEXT  

A Retrospective Poison Center Review of Varenicline-Exposed Patients
Kreshak et al.
The Annals of Pharmacotherapy 2009;43:1986-1991.
ABSTRACT | FULL TEXT  

Acute Hepatic Injury Associated with Varenicline in a Patient with Underlying Liver Disease
Franck and Sliter
The Annals of Pharmacotherapy 2009;43:1539-1543.
ABSTRACT | FULL TEXT  

Smoking cessation pharmacotherapy
Frishman
Ther Adv Cardiovasc Dis 2009;3:287-308.
ABSTRACT  

Combination treatment with varenicline and nicotine replacement therapy
Ebbert et al.
Nicotine Tob Res 2009;11:572-576.
ABSTRACT | FULL TEXT  

Safety and Effectiveness of Varenicline in a Veteran Population with a High Prevalence of Mental Illness
Purvis et al.
The Annals of Pharmacotherapy 2009;43:862-867.
ABSTRACT | FULL TEXT  

An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts
Bader et al.
Tobacco Control 2009;18:34-42.
ABSTRACT | FULL TEXT  

Varenicline-Associated Acute Renal Failure
Bird and Vesta
The Annals of Pharmacotherapy 2008;42:1908-1911.
ABSTRACT | FULL TEXT  

Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression
Pirmoradi et al.
Am J Health Syst Pharm 2008;65:1624-1626.
ABSTRACT | FULL TEXT  

Smoking: A Deadly Pleasant Habit--Is There a Way Out?
Richter
ANGIOLOGY 2008;59:49S-53S.
ABSTRACT  

Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials
Eisenberg et al.
CMAJ 2008;179:135-144.
ABSTRACT | FULL TEXT  

Update on pharmacologic and nonpharmacologic therapies for smoking cessation
Schmelzle et al.
cfp 2008;54:994-999.
ABSTRACT | FULL TEXT  

{blacktriangledown}Varenicline for smoking cessation
DTB 2008;46:33-36.
ABSTRACT | FULL TEXT  

Hypomania with Agitation Associated with Varenicline Use in Bipolar II Disorder
Morstad et al.
The Annals of Pharmacotherapy 2008;42:288-289.
FULL TEXT  

Promising New Drug Could Help Smokers Kick the Habit
Holman
DOC News 2006;3:16-16.
FULL TEXT  

Another Arrow in the Quiver to Combat Smoking
Journal Watch Cardiology 2006;2006:4-4.
FULL TEXT  

New Weapon to Curb Smoking: No More Excuses to Delay Treatment.
Johnson
Arch Intern Med 2006;166:1547-1550.
FULL TEXT